Cancer Immunology, Immunotherapy

, Volume 60, Issue 1, pp 111–122

Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes

Original Article

DOI: 10.1007/s00262-010-0924-z

Cite this article as:
Su, Y., Jackson, E.K. & Gorelik, E. Cancer Immunol Immunother (2011) 60: 111. doi:10.1007/s00262-010-0924-z


Previous studies document that PGE2 and adenosine suppress production of inflammatory cytokines. The present study demonstrates for the first time that (1) PGE2 and 2-chloroadenosine (CADO; a stable analog of adenosine) directly inhibit the cytolytic function of human tumor-infiltrating lymphocytes (TILs); (2) the combination PGE2 and CADO have additive suppressive effects; and (3) the cooperative immunosuppressive actions of PGE2 and CADO are mediated via EP2 receptors (EP2Rs) and A2A receptors (A2ARs) and are due to amplification of cAMP production, activation of protein kinase A (PKA) and T cell receptor (TCR) inhibitor Csk leading to inhibition of Lck, ZAP-70 and Akt phosphorylation. (4) During ex vivo expansion, TILs undergo three stages of differentiation converting from TILs with high cytotoxic activity and relative resistance to combined EP2R/A2AR suppression (stage I) to TILs retaining high cytotoxicity and gaining sensitivity to combined suppression (stage II) and then to TILS that are less cytotoxic and very sensitive to combined suppression (stage III). (5) Finally, we find that pretreatment of TILs with non-inhibitory concentrations of EP2R agonists (such as PGE2 or butaprost) or A2AR agonists (such as CADO or CGS21680) increases their cytotoxic activity and induces resistance to EP2R and A2AR inhibitory signaling (cross-resistance) due to homologous and heterologous desensitization and internalization of EP2Rs and A2ARs, thus preventing their inhibitory signaling. We conclude that inducing resistance of TILs to the suppressive effects of PGE2 and adenosine in the tumor microenvironment could represent a novel strategy for improving the efficacy of adoptive immunotherapy.


Adenosine PGE2 Human CTLs Tumor immunology 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yunyun Su
    • 1
  • Edwin K. Jackson
    • 3
  • Elieser Gorelik
    • 1
    • 2
  1. 1.Department of PathologyUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  2. 2.Department of ImmunologyUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Department of Pharmacology and Chemical BiologyUniversity of Pittsburgh Medical SchoolPittsburghUSA

Personalised recommendations